Core Viewpoint - Alteogen Inc. has entered into an exclusive license agreement with Tesaro, Inc. for the development and commercialization of a subcutaneous formulation of dostarlimab using Alteogen's ALT-B4 technology [1][2]. Group 1: Financial Terms - Alteogen will receive an upfront payment of US$20 million and is eligible for milestone payments up to US$265 million based on the achievement of specific development, regulatory, and sales milestones [2]. - The company will also receive royalties on the sales of the commercialized product [2]. Group 2: Technology and Product Details - ALT-B4 is a proprietary human recombinant hyaluronidase enzyme developed using Hybrozyme™ technology, enabling large volume subcutaneous administration of drugs typically given via IV infusion [4]. - The technology works by temporarily hydrolyzing hyaluronan in the extracellular matrix, facilitating the subcutaneous delivery of medications [4]. Group 3: Company Overview - Alteogen Inc. is a South Korea-based biopharmaceutical company focused on developing and commercializing novel biologics, including Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars [5]. - The company was founded in 2008 and is listed on KOSDAQ under the ticker 196170.KQ [5].